Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the ...

Novo Nordisk CEO Mike Doustdar said on Tuesday the drugmaker expects headwinds in its international operations in 2026, as ...

Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of ...

Oral weight-loss drugs could account for a third or more of the overall GLP-1 market by 2030, a Novo Nordisk executive said ...

Novo Nordisk A/S (NOVO:CA) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 12:45 PM ESTCompany ...

Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

Novo Nordisk faces slowing growth, competition, regulatory risks, and Wegovy pricing pressure, with DCF showing fair ...

This week on "The Readout LOUD," a special live taping from #JPM26 featuring new Novo Nordisk CEO Mike Doustdar and biotech ...

Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay ...